NeOncoFRAx is at the forefront of personalized cancer immunotherapy. As our research and trials progress, we remain committed to transparent communication with the broader medical, scientific, and patient communities.
Nieuw vaccin tegen dodelijke vorm van kanker ‘leert’ immuunsysteem om tumor aan te vallen
We are preparing our first peer-reviewed manuscripts on neoantigen prediction, peptide synthesis methods, and trial design. Future publications will appear here as they are released.
